Biotech news for Wednesday, June 10, 2026, ranked by our 5-dimension investment framework — regulatory, technology, commercial, manufacturing, and narrative.
Jonathan Kitchen Stock futures rose, and crude oil benchmark prices fell on Tuesday as geopolitical anxieties showed signs of easing. Market sentiment was further lifted by a continuing tech sector recovery ahead of Friday’s highly anticipated SpaceX IPO. Here…
Andrii Dodonov TG Therapeutics ( TGTX ) on Tuesday announced the initiation of a potentially pivotal mid-stage trial for its lead asset, Briumvi, in myasthenia gravis, alongside encouraging early-stage trial data for an injectable formulation of the drug. Citi…
Shattuck Labs ( STTK ) received notices to exercise ~50.6M warrants, representing 96% of warrants issued in its August 2025 private placement. The warrant exercises are expected to generate total gross proceeds of ~$54.9M. As of March 31, 2026, the company had…
Aditxt ( ADTX ) a nnounced a definitive business combination agreement to take its wholly owned subsidiary Ignite Proteomics public. The transaction values Ignite at an implied equity value of ~$150M. Upon closing, Ignite is expected to separate from Aditxt an…
onurdongel/iStock via Getty Images Alterity Therapeutics ( ATHE ) and the FDA have reached on agreement on the details for the pharma' phase 3 program for ATH434, its candidate for the rare neurodegenerative disorder multiple system atrophy. The particulars in…
narvo vexar/iStock via Getty Images Chinese biotech Zai Lab Limited ( ZLAB ) announced late Monday that Chinese regulators approved its antibody-drug conjugate Tivdak, developed with Pfizer ( PFE ) and Genmab ( GMAB ), as a late-line treatment for adults with…
The targeted oncology sector is shifting after GSK ( GSK ) decided to buy Nuvalent ( NUVL ) for $10.6B. This massive deal proves that Wall Street has been underestimating the true value of advanced, highly precise cancer treatments. As Nuvalent ( NUVL ) leaves
William Barton/iStock Editorial via Getty Images GSK ( GSK ) has agreed to acquire U.S. biopharmaceutical company Nuvalent ( NUVL ) in a deal valued at approximately $10.6B. Under the agreement, GSK will launch a tender offer within ten business days to acquir…